The advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control.
By Pooja Toshniwal PahariaReviewed by Lily Ramsey, LLMJul 23 2024 In a recent article published in Science, researchers reviewed clinical studies on the advantages of glucagon-like peptide-1 medicines beyond glycemic and weight control.Introduction GLP-1 medications, used to treat primarily obesity and diabetes, reduce inflammation indirectly through weight reduction, neuronal GLP-1 receptor activation, and directly through T cell activation.
Cardiovascular, hepatic, and renal benefits of GLP-1 medicines GLP-1 medicines, mostly acylated peptides like semaglutide and liraglutide, have pleiotropic effects beyond weight and glycemic management, including renal and heart disease prevention. Their actions in lowering systemic inflammation have important implications for future clinical applications and medication development.
Clinical trials and animal research support GLP-1 medication usage to treat metabolic liver disease. Semaglutide is now in phase 3 clinical trials. However, hepatocytes do not express GLP-1R, making it difficult to appreciate its liver health advantages. Semaglutide can also assist heart failure patients. Indirect benefits include lower blood pressure, reduced atherogenic lipoproteins, improved blood glucose management, and weight loss.
The growing use of these medications has prompted concerns regarding their ability to influence central nervous system illness outcomes, including those of depression, excessive drug use and alcohol consumption, compulsive behaviors, and suicidal thoughts.
Glucagon Glucagon-Like Peptide-1 Obesity Alcohol Atherosclerosis Blood Cell Diabetes Efficacy Exenatide GLP-1 Glucose Heart Heart Disease Inflammation Kidney Kidney Disease Liver Liver Disease Mortality Myocardial Infarction Peptides Receptor Semaglutide Stroke Type 2 Diabetes Weight Loss
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesityIn a Perspective, Daniel Drucker highlights the growing body of evidence that hints at the potential of glucagon-like peptide-1 (GLP-1)-based medications in treating conditions other than diabetes and obesity, including cardiovascular disease and neurodegenerative disorders.
Read more »
Study reveals exercise and GLP-1 RA combination preserves bone health during weight lossCombining exercise with GLP-1 RA liraglutide results in significant weight loss while preserving bone health in adults with obesity.
Read more »
Exercise and GLP-1 RA appears effective for weight loss while preserving bone mineral densityFor adults with obesity, without diabetes, combining exercise with the glucagon-like peptide-1 receptor agonist (GLP-1 RA), liraglutide, is effective for weight loss, while preserving bone health, according to a study published online June 25 in JAMA Network Open.
Read more »
New study reveals how GLP-1 receptor agonists enhance preingestive fullnessGLP-1 receptor agonists promote the feeling of fullness before eating via neurons in the dorsomedial hypothalamus, according to a new study. The findings offer new insights into the neural pathways by which GLP-1 receptor agonists increase the feeling of fullness to prevent overconsumption of food, which is key in mitigating obesity.
Read more »
GLP-1 drugs found to lower cancer risk in diabetes patientsResearch finds that GLP-1 receptor agonists significantly reduce the risk of 10 out of 13 obesity-associated cancers in type 2 diabetes patients compared to insulins, but show varied results against metformin.
Read more »
Sister hormone of GLP-1 could lead to better weight-loss drugsMuch like the Cold War space race, the world's pharmaceutical giants are currently scrambling to produce the best weight-loss drug. They all want to be the first to explore the nooks and crannies of the body in order to be able to design the optimal drug. However, several pharmaceutical giants disagree on what the next step should be.
Read more »